Ask AI

Momentum in mTNBC: Clinical Integration of TROP2 ADCs for Patients Who Are Not Candidates for Immunotherapy

Explore current and emerging evidence for TROP2-directed ADCs in triple-negative breast cancer, including first-line treatment for patients who are not candidates for immunotherapy and later-line sequencing. Review individualized treatment selection and multidisciplinary prevention and management of ADC-associated toxicities.

TROP2 ADCs in mTNBC

Activity Information

Released: October 15, 2026